Titan Pharmaceuticals

Company profile

About

Titan Pharmaceuticals (NASDAQ:TTNP) focuses on the development of therapeutics for the treatment of chronic diseases, leveraging its proprietary long-term drug delivery platform, ProNeura. This innovative approach aims to improve the treatment of conditions like opioid addiction and chronic pain by ensuring consistent, long-term medication levels in the body, potentially reducing the need for frequent dosing. The company's key project, Probuphine, is an implant that delivers buprenorphine for the treatment of opioid addiction, marking a significant step towards addressing this growing epidemic. Titan Pharmaceuticals is dedicated to expanding its portfolio through the development of new therapies and partnerships, with the objective of enhancing patient care and addressing unmet medical needs in chronic disease management.

Snapshot

1992Year founded

4Employees

South San Francisco, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Titan Pharmaceuticals

Probuphine is Titan's innovative implant designed to deliver continuous, long-term treatment for opioid use disorder.
Ropinirole implant, in development for Parkinson’s disease, aims at providing steady medication levels, potentially improving patient outcomes.
T3 implant is being developed for hypothyroidism, potentially offering a more consistent alternative to daily oral thyroid hormone replacement therapy.
Spheramine, an earlier stage project, focuses on cell-based therapy for Parkinson’s disease, showcasing Titan's commitment to advanced treatment strategies.
Nalmefene implant, under early research, targets opioid overdose prevention, aiming to offer a long-lasting solution to this critical public health issue.
Fanapt® is an antipsychotic drug licensed from Vanda Pharmaceuticals, expanding Titan's portfolio into treatments for schizophrenia.